CSE: 2019-0105 – New Listing - Transcanna Holdings Inc.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
13
CSE: 2019-0105 – New Listing - Transcanna Holdings Inc. (TCAN)

TORONTO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- The common shares of Transcanna Holdings Inc., have been approved for listing on the CSE.

Listing and disclosure documents will be available at  www.thecse.com  on the trading date.

TransCanna Holdings Inc. is a cannabis branding, transportation and distribution company in California that assists cannabis cultivators and manufacturers in getting recognized by end-users and consumers.

________________________

Les actions ordinaires de Transcanna Holdings Inc. ont été approuvées à la cote du CSE.

Les documents de cotation et d'information seront disponibles sur www.thecse.com à la date de négociation.

TransCanna Holdings Inc. est une société californienne de promotion de la marque, de transport et de distribution de cannabis, qui aide les cultivateurs et les fabricants de cannabis à se faire reconnaître par les utilisateurs finaux et les consommateurs.

Issuer/Émetteur: Transcanna Holdings Inc.
Security Type/Titre: Common Shares/Actions ordinaires
Symbol(s)/Symbole(s): TCAN
Number of securities issued and outstanding/ Titres émis et en circulation: 16 995 654
Number of Securities reserved for issuance/ Titres réservés pour émission: 8 445 400
CSE Sector/Catégorie: Life Sciences/Sciences biologiques
CUSIP: 89356V 10 4
I SIN: CA 89356V 10 4 0
Boardlot/Quotité: 500
IPO Price/Prix: $0.50/0,50 $
Agent: Haywood Securities Inc.
Trading Currency/Monnaie de négociation: CDN$/$CDN
Listing Date/Date de l’inscription: le 8 janvier/January 2019
Trading Date/Date de negociation: le 9 janvier/January 2019
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: Le 30 novembre/November
Transfer Agent/Agent des transferts: Odyssey Trust Company

The Exchange is accepting Market Maker applications for TCAN. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail:  Listings@thecse.com

Pour toute question, pour obtenir de l’information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l’adresse:   Listings@thecse.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Madrigal Pharmaceuticals Rewards New Employees with Equity Awards

Updated Category News Views 100

Overview of Equity Inducement Awards Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a leading biopharmaceutical organization, has recently initiated equity inducement awards to welcome new talent to its dynamic team. This initiative demonstrates Madrigal's commitment to fostering a strong workforce geared towards tackling significant health challenges related to metabolic...

Continue Reading
Boston Metal Welcomes Roy Harvey to Enhance Board Leadership

Updated Category News Views 202

Boston Metal Appoints Industry Leader Roy Harvey Boston Metal, a prominent technology company that is transforming the landscape of global metals production, has made a significant move by appointing Roy Harvey to its Board of Directors. This decision is pivotal as Boston Metal gears up for the commercial rollout of its groundbreaking Molten Oxide Electrolysis (MOE)...

Continue Reading
RBL LLC Partners with Carnrite Ventures for Biotech Growth

Updated Category News Views 125

RBL LLC Partners with Carnrite Ventures for Biotech Growth RBL LLC, a leading biotech venture creation studio, is excited to announce a significant investment from Carnrite Ventures. This partnership aims to enhance the rapid development of their robust pipeline of innovative therapeutic companies. According to Paul Wotton, the managing partner at RBL, "Carnrite's...

Continue Reading
OncoC4 and AcroImmune Merger: A Milestone in Immunotherapy

Updated Category News Views 106

Introducing the OncoC4 and AcroImmune Merger OncoC4, Inc. has just announced a thrilling merger with AcroImmune, a strategic union that promises to significantly boost OncoC4's standing in the biopharmaceutical sector. This collaboration brings together two companies dedicated to pioneering advancements in cancer treatment, with a special focus on developing unique...

Continue Reading
Rezolve AI Celebrates Major Investment Transforming AI Landscape

Updated Category News Views 92

Rezolve AI Excited About $30 Billion AI Investment Rezolve AI (NASDAQ: RZLV), well-known for its cutting-edge AI-driven commerce solutions, is enthusiastic about the recent announcement from Microsoft and BlackRock. These influential tech companies plan to invest $30 billion into AI infrastructure, a decision that could profoundly alter the landscape of the artificial...

Continue Reading